Background Human T-cell Iymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) is a chronic inflammatory disease that primarily affects the spinal cord and may be a neurological syndrome that is clinically similar to multiple sclerosis (MS). Myelin basic protein (MBP) in the cerebrospinal fluid (CSF) of MS patients is generally measured by radioimmunoassay. We have recently established a sensitive enzyme-linked immunosorbent assay (ELISA) and measured the MBP concentrations in CSF and serum of HAMITSP patients.
Introduction
Human T-cell lymphotropic virus type 1 (HTLV-1)associated myelopathy (HAM)/tropical spastic paraparesis (TSP) may involve spinal cord pathology. Much evidence suggests that HAM/TSP is similar to multiple sclerosis (MS). The neuropathological findings involve demyelination and T-ceH Inflltrates.' T2-weighted magnetic resonance imaging shows multifocallesions in the cerebral white matter in both dlseases.i Moreover, biochemical profiles that show the presence of an oligoclonal band and mild pleocytosis in the cerebrospinal fluid (CSF). favourable responses to corticosteroids and interferon-a: or -{3 and predominance in adult women have been reported for both disorders. J. 3.4 Until now, however, elevated levels of myelin basic protein (MBP) have not been reported in the CSF and serum of patients with HAM/TSP. We recently developed a sensitive enzyme-linked immunosorbent assay (ELISA) that is capable of measuring MBPat a concentration as low as 30 ng/L. 5 We have investigated CSF and serum MBP concentrations in 46 patients with HAM/TSP.
Subjects and methods
We obtained CSFand serum samples from HAM/TSP patients (19 men, 27 women, mean age 50 years; age range 32-74 years), from MS patients (32 men. 52 women, mean age 45 years; age range 16-68 years) and from 45 patients (20 men. 25 women; mean age 47 years; age range 30-67 years) with nonneurological diseases (17 with muscular dystrophy, 10 with thyroiditis and 18 with rheumatoid arthritis). As controls. serum samples were obtained from 70 healthy subjects (30 men, 40 women; mean age 51 years; age range 35-70 years). The study protocol was approved by the ethics committee of the Utano National Hospital and informed consent was obtained from all subjects.
MBP was isolated from bovine brain. Bovine MBP was used as the standard protein and antigen source for the anti-MBP IgG. Rabbit anti-bovine MBPIgG was biotinylated with 5-(N-succinimidyl-oxycarbonyl) pentyl-D-biotinamide (Dojindo, Kumamoto, [apanj.! MBP was detected by a two-site ELISA as described elsewhere.! A microtitre plate was coated with antibovine MBP IgG (3 mg/L) diluted with 10 mmol/L carbonate buffer, pH 9'3 for 1 h at room temperature. After the plate was washed twice. the unoccupied protein-binding sites in each well were blocked by incubation with carbonate buffer containing 0·5% bovine serum albumin (BSA) for 1 h at room temperature. One hundred microlitres of standard MBP, undiluted CSFsample. or serum sample diluted twofold with washing buffer (50 mmol/L Tris-HCI buffer. pH 7·0. containing 0·2 mol/L NaCI. 10 mmol/L CaCI.2 and 0·1% Triton X-lOO) containing 1%BSAwas added to the wells and the plate was incubated for 1 h at room temperature. After further washing with washing buffer, biotinylated anti-MBP antibody conjugate (20 mg/L) was added, and the plate was incubated for 1 h at room temperature. After washing. the plate was incubated for 1 h at room temperature with streptavidin-linked horseradish peroxidase 
Results and discussion
Elevated levels of CSF MBPsecondary to acute myelin breakdown are present in many patients with active disease of the nervous system (e.g. MS. 5 transverse myelitis. central pontine myelinolysis. HIVencephalopathy, neuro-Behcet's dlsease") and provide a marker for central nervous system demyelination. CSF MBP concentrations greater than 102 ng/L were considered positive. HAM/TSP is a chronic inflammatory disease that primarily affects the spinal cord and may be a neurological syndrome clinically similar to MS. Significantly higher CSF MBPconcentrations were detected in 61% (14/23) ofHAM/TSP patients (maximum value 487 ng/L: median 116 ng/L: minimum value 33 ng/ mL) than in patients with non-neurological diseases (P<O'OOl by Mann-Whitney V-test) (Fig.1a) . Serum MBPlevels were also higher in 9% (4/46) of HAM/TSP patients than in patients with non-neurological diseases or in healthy controls ( < 50 ng/L) ( Fig. 1b) . Longitudinal studies of CSF collected serially « 12 months) from six individuals showed approximately the same continuous concentration in each person who was positive for CSF MBP.
In contrast. 52 MS patients with clinically active disease had a markedly increased median CSF MBP concentration (460 ng/L) and a high frequency of increased results (81%). whereas most of the 32 clinically inactive MS patients had MBP concentrations that were not increased (median 65 ng/L: frequency of increased values. 19%).Within 4 weeks after an acute attack. the CSF MBP decreased rapidly to normal or low concentrations. The serum MBP concentration was negligible -in rare cases. at a low concentration ( < 389 ng/L) -even in MS patients who had a markedly high MBP concentration (SOO-8000 ng/L) in their CSF. This ELISA is more specific than radioimmunoassay. and can be used to measure MBP in serum as well as in CSF samples as a diagnostic indicator for myelin breakdown. We have detected CSF MBP at low concentrations at high prevalence (61%) and serum MBP in 9% of patients with HAM/TSP. Thus the ELISA for MBPcan provide a useful indicator. not only for central active demyelination as in MS. but also for this type of spinal cord demyelination.
